Compare Illumina, Inc. (ILMN) vs Palo Alto Networks Inc (PANW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Palo Alto Networks Inc — how do they compare? Illumina, Inc. trades at $180.13 (market cap $27.94B), while Palo Alto Networks Inc trades at $353.18 (market cap $284.16B). The key difference: Palo Alto Networks Inc is far larger — about 10.2× Illumina, Inc.'s market cap, and Palo Alto Networks Inc is trading nearer its 52-week high, Illumina, Inc. nearer its low. Which is the better fit depends on your goals.
| ILMN | PANW | |
|---|---|---|
Market Cap | $27.94B | $284.16B |
Sector | Health | Technology |
52-Week High | $194.33 | $358.68 |
52-Week Low | $91.00 | $141.67 |
Enterprise Value | $29.33B | $283.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
Palo Alto Networks (PANW) trades at $353.85, down 1.35% on the day but showing strong bullish momentum with shares roughly doubling over three months. The stock exhibits robust fundamentals with consistent earnings beats, revenue growth to $9.22B in 2025, and a high gross margin of 71.94%. Technical indicators signal a bullish trend, supported by positive moving averages, though RSI levels suggest potential overbought conditions near-term.
Outlook remains positive driven by AI-driven cybersecurity demand and platformization strategy, but high valuation ratios (P/E 311.9, P/S 24.9) pose risks. Analyst consensus is strongly bullish (74% Buy ratings) with a $339.56 price target, though competition and integration costs are key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →
